Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086246 | 1.00 | SIGMAR1 (0.53) | SIGMAR1PREPACE2NPSR1TSHR | |
| SCHEMBL3086248 | 1.00 | SIGMAR1 (0.53) | SIGMAR1PREPACE2NPSR1TSHR | |
| SCHEMBL31211418 | 0.94 | SIGMAR1 (0.49) | SIGMAR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL31211342 | 0.94 | SIGMAR1 (0.49) | SIGMAR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL30511005 | 0.80 | PREP (0.47) | SIGMAR1PREPACE2NPSR1TSHR | |
| SCHEMBL34474623 | 0.80 | PREP (0.47) | SIGMAR1PREPACE2NPSR1TSHR | |
| SCHEMBL31520646 | 0.80 | SMN1; SMN2 (0.50) | SIGMAR1NPSR1PDK1PDK2PDK3 | |
| SCHEMBL31427469 | 0.80 | SIGMAR1 (0.45) | SIGMAR1PREPACE2NPSR1 | |
| SCHEMBL31520694 | 0.80 | PDK1 (0.48) | SIGMAR1PDK1PDK2PDK3PDK4 | |
| SCHEMBL24509187 | 0.79 | SIGMAR1 (0.46) | SIGMAR1NPSR1PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| EP-2144630-A2 | CHK1 INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | AstraZeneca AB (SE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| WO-2008132500-A2 | CHKL INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | SIGMAR1 4771/4885PREP 3747/4885ACE2 3605/4885 |
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | CHEK1, CHEK2, MCL1 | SIGMAR1 4841/4885PREP 3832/4885ACE2 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.